Ignite Creation Date:
2024-05-06 @ 10:10 AM
Last Modification Date:
2024-10-26 @ 12:26 PM
Study NCT ID:
NCT03183609
Status:
COMPLETED
Last Update Posted:
2024-02-01
First Post:
2017-06-07
Brief Title:
Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies AGA IG
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Confirmatory Double-Blind Placebo-Controlled Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies AGA IG
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study purpose is to conduct a confirmatory double-blind randomized controlled trial in an inpatient setting of the effects of a tightly controlled gluten-free diet GFD to improve negative symptoms in people with schizophrenia or schizoaffective disorder who have antibodies to gliadin AGA IgG As part of the project investigators will also confirm outcomes such as cognitive symptoms changes in peripheral and central inflammation as well as gutblood brain barrier permeability
Detailed Description:
This study is a randomized double blind clinical trial being funded by NIMH Investigators will need to enroll 40 cases with AGA IgG positivity in order to present a powered and convincing result about the efficacy of gluten withdrawal in the subpopulation of persons with schizophrenia with elevated AGA IgG levels Investigators will recruit a minimum 50 to ensure they are well powered without question and to account for dropouts Investigators will use a battery of measures of peripheral and central inflammation as well as gut permeability at baseline and endpoint to confirm the relationship of these outcomes to changes in AGA IgG and symptom changes in the clinical trial Investigators will test negative symptoms as a primary outcome but will test changes in other symptom domains such as positive symptoms After the completion of the 5 week confirmatory study investigators will discharge participants and follow them for 8 weeks in their own environment to test the maintenance of the effect following the stringent GFD and provide education on gluten free shopping cooking and eating
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None